Sign in

CIK 0001601830

  • Large accelerated filer

RECURSION PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RXRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464099738
Phone
+1 385-269-0203
Business address
41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
Former names
Recursion Pharmaceuticals, LLC
  1. 3 Insider Initial Statement of Ownership
  2. 4 Planned sale Director sold 220,000 shares at $4.36 ($959,200)
  3. 4 Planned sale Director sold 40,000 shares at $4.25 ($170,000)
  4. 4 Grant or award Director acquired 3,571 shares (grant or award)
  5. 4 Grant or award Director acquired 2,381 shares (grant or award)
  6. 4 Planned sale Chief Financial Officer sold 21,383 shares at $4.18 ($89,381)
  7. 4 Planned sale Chief R&D Commercial Officer sold 124,403 shares at $4.41 ($548,592)
  8. 4 Planned sale Chief Executive Officer sold 40,000 shares at $4.50 ($180,000)
  9. 4 Shares withheld for taxes Chief Financial Officer gave up 7,057 shares (to pay taxes)
  10. 4 Planned sale Chief Executive Officer sold 40,000 shares at $4.63 ($185,200)
  11. 4 Planned sale Director sold 220,000 shares at $4.37 ($961,400)
  12. 4 Shares withheld for taxes Chief Financial Officer gave up 2,271 shares (to pay taxes)
  13. 4 Shares withheld for taxes Chief Financial Officer gave up 11,908 shares (to pay taxes)
  14. 4 Shares withheld for taxes Chief R&D Commercial Officer gave up 17,584 shares (to pay taxes)
  15. 4 Planned sale Chief Executive Officer sold 40,000 shares at $4.16 ($166,400)
  16. 4 Grant or award Chief R&D Commercial Officer acquired 84,925 shares (grant or award)
  17. 4 Planned sale Chief Executive Officer sold 40,000 shares at $5.21 ($208,400)
  18. 4 Planned sale Chief Executive Officer sold 100,000 shares at $5.70 ($570,000)
  19. 4 Planned sale Chief Executive Officer sold 100,000 shares at $6.04 ($604,000)
  20. 4 Grant or award Director acquired 1,961 shares (grant or award)

Page 4 of 26 · 512 filings